A5033260770- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Peptidase Inhibition and Analysis
- Diabetes Management and Education
- Cancer, Hypoxia, and Metabolism
- Sexual Differentiation and Disorders
- Diabetes Management and Research
- Pancreatic function and diabetes
- Antiplatelet Therapy and Cardiovascular Diseases
- Neuropeptides and Animal Physiology
- Hormonal and reproductive studies
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Platelet Disorders and Treatments
Kyoto University
2025
Kitano Hospital
2019-2022
Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are widely used as antidiabetic and anti-obesity agents. Although conventional GLP-1 RAs such liraglutide semaglutide acylated with fatty acids to delay their degradation by dipeptidylpeptidase-4 (DPP-4), the manufacturing process is challenging. We previously developed selectively lipidated peptides at only tryptophan residue (peptide A having one 8-amino-3,6-dioxaoctanoic acid (miniPEG) linker B three miniPEG linkers). In this...
Previous studies suggested that β-cell function markers such as fasting and postprandial serum C-peptide increment (FCPR, PCPR, ΔCPR, respectively) may be useful in estimating glycemic response to glucagon-like peptide-1 receptor agonists. However, it remains elusive whether baseline control confounds these markers. Here we aimed identify the least confounded investigate could predict dulaglutide. We evaluated FCPR, ΔCPR levels patients with type 2 diabetes who initiated dulaglutide...
To conduct a study on glycemic control improvement by appropriate re-education the self-injection technique (SIT) in patients with diabetes mellitus undergoing insulin therapy.Patients who received SIT and were treated for more than year re-educated. For observation period of six months, subjects' was checked, hemoglobin A1c (HbA1c) levels measured at each visit. HbA1c levels, doses, behavioral changes investigated baseline end period.In per-protocol set population, level decreased 0.2 %...
Aims: The effect of β-cell function on glycemic response to dulaglutide (DU) is not fully understood in clinical settings. We explored a suitable marker predict DU patients with type 2 diabetes (T2D). Methods: retrospectively analyzed 141 who commenced once-weekly 0.75 mg after undergoing meal tolerance test (MTT) standardized from September 2015 December 2019 at our hospital. was assessed by fasting and 2h postprandial serum C-peptide immunoreactivity (CPR) as well increment CPR (dCPR) the...